Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytosolic 5'-nucleotidase 1B (NT5C1B) is an intracellular enzyme that catalyzes the hydrolysis of nucleotide monophosphates, predominantly AMP, to release inorganic phosphate and the corresponding nucleoside—typically adenosine. As a cytosolic member of the 5'-nucleotidase family, it controls the intracellular levels of AMP and contributes to the regulation of cellular nucleotide pools and adenosine metabolism. The enzyme plays a housekeeping metabolic role rather than being a key drug target or clinical biomarker. Mutations or alterations in NT5C1B activity have been associated with rare genetic syndromes, such as Laurence-Moon syndrome and pontocerebellar hypoplasia, but NT5C1B is not currently a focus of targeted therapeutics, and there are no known drugs that interact specifically with this protein. It is considered functionally important for nucleotide turnover and purine metabolism in various tissues.
Not applicable (no current drugs directly targeting this enzyme; mechanism is hydrolysis of nucleotide monophosphates)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytosolic 5'-nucleotidase 1B (NT5C1B).